1. Nomograms for Bladder Cancer
Shahrokh F. Shariat, Vitaly Margulis, Yair Lotan, Francesco Montorsi, Pierre I. Karakiewicz 
European Urology 
Volume 54, Issue 1, Pages (July 2008)
DOI: /j.eururo
Copyright © 2008 European Association of Urology Terms and Conditions

2. Fig. 1
Bladder cancer-specific survival nomogram in 731 patients treated with radical cystectomy and bilateral lymphadenectomy for urothelial carcinoma of the bladder. Instructions for nomogram use: Locate patient values at each axis. Draw a vertical line to the “Point” axis to determine how many points are attributed for each variable value. Sum the points for all variables. Locate the sum on the “Total Points” line. Draw a vertical line towards the “2Yrs.Surv.Prob.,” “5Yrs.Surv.Prob.,” and “8Yrs.Surv.Prob.” axes to determine, respectively, the 2- yr, 5-yr, and 8-yr survival probabilities. Reprinted with permission of Shariat et al. Clin Cancer Res 2006;12:6663 [14].
European Urology  , 41-53DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions

3. Fig. 2
Nomograms for (A) recurence of any transitional cell carcinoma; (B) recurrence of grade 3 Ta or T1 or of carcinoma in situ (CIS); (C) recurrence of ≥T2 stage transitional cell carcinoma in 2681 patients who underwent office cystoscopy for detection of bladder cancer recurrence after treatment of stage Ta, T1, or CIS urothelial carcinoma of the urinary bladder. Reprinted with permission of Shariat et al. J Urol 2005;173:1518 [30].
European Urology  , 41-53DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions

4. Fig. 3
European Organization for Research and Treatment of Cancer scoring system and risk tables for stage Ta T1 bladder cancer. The risk tables allow estimation of the probability of recurrence and progression in patients with stage Ta T1 bladder cancer based on number of tumors, tumor size, prior recurrence rate, T category, concomitant carcinoma in situ, and grade.
European Urology  , 41-53DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions

5. Fig. 4
Postoperative nomogram that integrates the immunohistochemical status of five established cell cycle regulatory biomarkers (p53, pRB, p21, p27, and cyclin E1) with standard histopathologic variables for predicting 1-, 2- and 5-yr risk of disease recurrence in 191 patients with pTa–3 N0 M0 urothelial carcinoma of the bladder treated with radical cystectomy and bilateral lymphadenectomy. Instructions for physicians: Locate the patient's T stage on the sex axis. Draw a straight line up to the points axis to determine how many points toward recurrence the patient should receive. Repeat this process for each of the remaining axes, drawing a straight line each time to the points axis. Sum the points received for each predictive variable and locate this number on the total points axis. Draw a straight line down from the total points to one of the recurrence-free prediction (RFS) axes for the patient's specific risk of remaining free from recurrence for 1, 2, and 5 yr. Reprinted with permission of Shariat et al. Cancer. In press [31].
European Urology  , 41-53DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions